Antimicrobial activity of levofloxacin – M33 peptide conjugation or combination

Ceccherini, Federica; Falciani, Chiara; Onori, Martina; Scali, Silvia; Pollini, Simona; Rossolini, Gian María; Bracci, Luisa; Pini, Alessandro

doi:10.1039/c5md00392j

Cited by 13 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The M33 tetra-branched peptide, designed and optimised from an E. coli phage library, acts complementary to levofloxacin against E. coli and P. aeruginosa; however, its conjugation to levofloxacin did not substantially increase the activity of M33 alone [113]. A further study demonstrated that M33's activity extends to AG, CP, PC, and RF classes against A. baumannii and K. pneumoniae [114].…”

Section: De Novo Hdpsmentioning

confidence: 95%

Complementary Activities of Host Defence Peptides and Antibiotics in Combating Antimicrobial Resistant Bacteria

Lennard,

Hiemstra,

Nibbering

2023

Antibiotics

View full text Add to dashboard Cite

Due to their ability to eliminate antimicrobial resistant (AMR) bacteria and to modulate the immune response, host defence peptides (HDPs) hold great promise for the clinical treatment of bacterial infections. Whereas monotherapy with HDPs is not likely to become an effective first-line treatment, combinations of such peptides with antibiotics can potentially provide a path to future therapies for AMR infections. Therefore, we critically reviewed the recent literature regarding the antibacterial activity of combinations of HDPs and antibiotics against AMR bacteria and the approaches taken in these studies. Of the 86 studies compiled, 56 featured a formal assessment of synergy between agents. Of the combinations assessed, synergistic and additive interactions between HDPs and antibiotics amounted to 84.9% of the records, while indifferent and antagonistic interactions accounted for 15.1%. Penicillin, aminoglycoside, fluoro/quinolone, and glycopeptide antibiotic classes were the most frequently documented as interacting with HDPs, and Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, and Enterococcus faecium were the most reported bacterial species. Few studies formally evaluated the effects of combinations of HDPs and antibiotics on bacteria, and even fewer assessed such combinations against bacteria within biofilms, in animal models, or in advanced tissue infection models. Despite the biases of the current literature, the studies suggest that effective combinations of HDPs and antibiotics hold promise for the future treatment of infections caused by AMR bacteria.

show abstract

Section: De Novo Hdpsmentioning

confidence: 95%

Complementary Activities of Host Defence Peptides and Antibiotics in Combating Antimicrobial Resistant Bacteria

Lennard,

Hiemstra,

Nibbering

2023

Antibiotics

View full text Add to dashboard Cite

show abstract

“…Зниження афінності виникає в результаті спонтанних мутацій, які призводять до амінокислотних замін в ділянках поліпептидних ланцюгів ДНК-гірази чи топоізомерази IV, що входять до складу "хінолонової кишені". У ході проведених досліджень встановлено, що ДНК-гіраза грампозитивних бактерій, на відміну від грамнегативних, менш чутлива до інгібуючого впливу фторхінолонів, а основною мішенню препаратів у грампозитивних мікроорганізмів є топоізомераза IV [5]. У дослідженні Boselli E. та співавт.…”

Section: механізми дії та резистентностіunclassified

Role and place of levofloxacin in the treatment of community-acquired pneumonia

Dmytriiev¹,

Назарчук²,

Babina³

2021

prmd

View full text Add to dashboard Cite

Lower respiratory tract infections are the third mortality cause in the world and the first mortality cause in low-income countries. Community-acquired pneumonia (CAP) is a dangerous infectious pathology, especially in children younger than 5 years, elderly people and patients with compromised immunity. Antibiotic therapy is a standard treatment method for CAP. But an increase in antibiotics use caused a development of resistance in bacteria and onset of adverse events in humans. A new class of fluorchinolones is widely used nowadays in clinical practice. They have good activity against Gram-negative bacteria, as early chinolones, as well as against Gram-positive bacteria, such as pneumococci and atypical bacteria. An increasing amount of penicillin-resistant streptococcal pneumonia leads to more intensive studies of the use of new chinolones. In this review the data of 750 mg levofloxacin is presented. It is used in short courses for the treatment of severe and moderate CAP. Taking into account the broad spectrum of activity of levofloxacin ad bactericidal activity of this antibiotic, it can be a potential alternative therapy for the treatment of children and adults with CAP, especially with a tendency of an increase in antibiotic resistance of pneumococcus.

show abstract

“…The conjugate magainin II-vancomycin demonstrated higher activity against vancomycin-resistant Enterococci compared to vancomycin alone [ 139 ]. Other peptides such as M33, indolicidine, or transactivating transcriptional activator (TAT) have been conjugated with levofloxacin for POT [ 140 ]. M33 is a branched synthetic peptide with a broad-spectrum antibacterial effect by binding lipopolysaccharide (LPS) on the surface of Gram-negative bacteria [ 141 ].…”

Section: Antimicrobial Peptides (Amps) In Combatting Amrmentioning

confidence: 99%

The Strategies of Pathogen-Oriented Therapy on Circumventing Antimicrobial Resistance

et al. 2020

View full text Add to dashboard Cite

The emerging antimicrobial resistance (AMR) poses serious threats to the global public health. Conventional antibiotics have been eclipsed in combating with drug-resistant bacteria. Moreover, the developing and deploying of novel antimicrobial drugs have trudged, as few new antibiotics are being developed over time and even fewer of them can hit the market. Alternative therapeutic strategies to resolve the AMR crisis are urgently required. Pathogen-oriented therapy (POT) springs up as a promising approach in circumventing antibiotic resistance. The tactic underling POT is applying antibacterial compounds or materials directly to infected regions to treat specific bacteria species or strains with goals of improving the drug efficacy and reducing nontargeting and the development of drug resistance. This review exemplifies recent trends in the development of POTs for circumventing AMR, including the adoption of antibiotic-antibiotic conjugates, antimicrobial peptides, therapeutic monoclonal antibodies, nanotechnologies, CRISPR-Cas systems, and microbiota modulations. Employing these alternative approaches alone or in combination shows promising advantages for addressing the growing clinical embarrassment of antibiotics in fighting drug-resistant bacteria.

show abstract

Antimicrobial activity of levofloxacin – M33 peptide conjugation or combination

Abstract: M33 is a branched antimicrobial peptide against Gram-negative bacteria. We reported its conjugation with levofloxacin and its antibacterial activity.

Cited by 13 publications

References 13 publications

Complementary Activities of Host Defence Peptides and Antibiotics in Combating Antimicrobial Resistant Bacteria

Complementary Activities of Host Defence Peptides and Antibiotics in Combating Antimicrobial Resistant Bacteria

Role and place of levofloxacin in the treatment of community-acquired pneumonia

The Strategies of Pathogen-Oriented Therapy on Circumventing Antimicrobial Resistance

Contact Info

Product

Resources

About